{
  "patent_number": "US 12168044",
  "country": "US",
  "title": "Treating Liver Cancer with Specially Trained Immune Cells",
  "original_title": "Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers",
  "summary": "This patent describes a method for treating hepatocellular cancer by giving patients specially activated immune cells that are trained to recognize and kill cancer cells displaying a specific protein fragment.",
  "what_it_does": "This patent describes a method for treating hepatocellular cancer, a type of liver cancer, by administering activated T cells to a patient. These T cells are specifically designed to kill cancer cells that display a particular peptide, KVLEHVVRV (SEQ ID NO: 1), on their surface, bound to an MHC class I molecule (claim 1). The activated T cells can be created in two main ways: either by genetically modifying T cells with a specific T cell receptor (TCR) that recognizes the target peptide (claim 2), or by training T cells outside the body using special 'antigen presenting cells' that display the peptide (claim 3). The treatment can also include giving additional helper medicines, called adjuvants, such as IL-2, IL-7, or IL-15, to boost the immune response (claim 4). For example, a patient with hepatocellular cancer could receive an infusion of their own T cells, modified in a lab to target the KVLEHVVRV peptide found on their tumor cells.",
  "what_it_does_not_cover": [
    "Does not cover treating cancers other than hepatocellular cancer.",
    "Does not cover targeting cancer cells with peptides other than KVLEHVVRV (SEQ ID NO: 1).",
    "Does not cover methods where the T cells do not bind the target peptide in a complex with an MHC class I molecule.",
    "Does not cover cancer immunotherapies that do not involve administering activated T cells, such as traditional vaccines using the peptide alone."
  ],
  "filed": "2023-10-19",
  "granted": "2024-12-17",
  "expires": "2043-10-19",
  "status": "active",
  "holder": "Immatics Biotechnologies",
  "holder_url": "https://patentbrief.org/company/immatics-biotechnologies",
  "inventors": [
    {
      "name": "Oliver Schoor",
      "url": "https://patentbrief.org/inventor/oliver-schoor"
    },
    {
      "name": "Andrea MAHR",
      "url": "https://patentbrief.org/inventor/andrea-mahr"
    },
    {
      "name": "Toni Weinschenk",
      "url": "https://patentbrief.org/inventor/toni-weinschenk"
    }
  ],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "immunotherapy",
    "gene_editing"
  ],
  "abstract": "The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.",
  "url": "https://patentbrief.org/patent/us/12168044/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-non-small-",
  "markdown_url": "https://patentbrief.org/patent/us/12168044/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-non-small-/md",
  "google_patents_url": "https://patents.google.com/patent/US12168044",
  "relatedPatents": [
    {
      "patentNumber": "10314897",
      "countryCode": "US",
      "title": "How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer",
      "url": "https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca"
    },
    {
      "patentNumber": "9328156",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Attack Cancer",
      "url": "https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer"
    },
    {
      "patentNumber": "9481728",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Fight CD19 Cancers",
      "url": "https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer"
    },
    {
      "patentNumber": "20160166668",
      "countryCode": "US",
      "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
      "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer"
    },
    {
      "patentNumber": "12163952",
      "countryCode": "US",
      "title": "Predicting and Treating Dangerous Side Effects in CAR T-Cell Therapy",
      "url": "https://patentbrief.org/patent/us/12163952/determining-toxicity-risk-in-car-t-cell-therapy"
    }
  ]
}